Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Operating Expenses (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Operating Expenses for 13 consecutive years, with $26.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 4.55% to $26.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $113.1 million, a 4.93% increase, with the full-year FY2024 number at $111.3 million, down 1.88% from a year prior.
  • Operating Expenses was $26.4 million for Q3 2025 at Theravance Biopharma, down from $28.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $98.1 million in Q1 2021 to a low of $21.6 million in Q3 2022.
  • A 5-year average of $39.5 million and a median of $29.9 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: plummeted 67.68% in 2022, then increased 15.99% in 2025.
  • Theravance Biopharma's Operating Expenses stood at $66.8 million in 2021, then plummeted by 51.98% to $32.1 million in 2022, then fell by 23.78% to $24.5 million in 2023, then increased by 14.32% to $28.0 million in 2024, then decreased by 5.4% to $26.4 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Operating Expenses are $26.4 million (Q3 2025), $28.9 million (Q2 2025), and $29.8 million (Q1 2025).